As ever in the often quick-developing biotech and pharmaceutical sectors on Tuesday, companies posted a mix of positive and ...

CNS Pharmaceuticals said its Berubicin treatment for an aggressive and usually fatal brain cancer didn't show a statistically significant difference in overall survival during a clinical trial, ...

R&D innovation is likely to remain a major focus area in 2025 . M&A activity is also expected to remain strong, particularly with Trump’s return to the White House.Regular pipeline setbacks, slow ramp ...

POOR PIERRE — Mere months ago, the Conservative Party in Canada looked headed towards a landslide victory. Its leader, Pierre Poilievre, was ascendant and drawing rave reviews from much of the ...

Me's drugs and patents — including two possible deals — could be key to its exit out of Chapter 11 bankruptcy protection.

Monte Rosa Therapeutics' stock falls as MRT-2359 faces challenges in targeting CRPC. Click here to read an analysis of GLUE ...

Bayer was ordered to pay more than $2 billion by a jury in a Georgia state court in the latest legal case surrounding alleged ...

Merck and Bristol-Myers Squibb are key players in cancer treatment. Find out why MRK and BMY stocks have different prospects ...

Australia is considering a World Trade Organisation challenge against US President Donald Trump’s steel and aluminium tariffs ...

These ratings convey expectations for the relative performance of Ionis Pharmaceuticals compared to the broader market. Price Targets: Analysts set price targets as an estimate of a stock's future ...

Ionis Pharmaceuticals IONS underwent analysis by ... Typically, analysts will rate each stock once a quarter. Some analysts will also offer forecasts for metrics like growth estimates, earnings ...

(RTTNews) - The Hong Kong stock market has moved lower in consecutive ... CNOOC advanced 0.91 percent, CSPC Pharmaceutical sank 1.24 percent, Galaxy Entertainment shed 1.23 percent, Hang Lung ...